Lineage Cell Therapeutics Inc Shares Rise 2.11% From The Lows – But Will They Continue?

In last trading session, Lineage Cell Therapeutics Inc (AMEX:LCTX) saw 0.47 million shares changing hands with its beta currently measuring 1.56. Company’s recent per share price level of $0.95 trading at $0.0 or 0.29% at ring of the bell on the day assigns it a market valuation of $166.24M. That closing price of LCTX’s stock is at a discount of -66.32% from its 52-week high price of $1.58 and is indicating a premium of 2.11% from its 52-week low price of $0.93. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.53 million shares which gives us an average trading volume of 446.00K if we extend that period to 3-months.

For Lineage Cell Therapeutics Inc (LCTX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.43. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.03 in the current quarter.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information

Upright in the green during last session for gaining 0.29%, in the last five days LCTX remained trading in the red while hitting it’s week-highest on Monday, 11/13/23 when the stock touched $0.95 price level, adding 10.38% to its value on the day. Lineage Cell Therapeutics Inc’s shares saw a change of -18.80% in year-to-date performance and have moved -8.65% in past 5-day. Lineage Cell Therapeutics Inc (AMEX:LCTX) showed a performance of -19.49% in past 30-days. Number of shares sold short was 6.15 million shares which calculate 13.55 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $5.50 to the stock, which implies a rise of 82.73% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $7.00. It follows that stock’s current price would drop -636.84% in reaching the projected high whereas dropping to the targeted low would mean a loss of -321.05% for stock’s current value.

Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts

Statistics highlight that Lineage Cell Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -29.63% of value to its shares in past 6 months, showing an annual growth rate of -6.67% while that of industry is 14.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. This year revenue growth is estimated to fall -35.30% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.07 million for the same. And 3 analysts are in estimates of company making revenue of $690k in the next quarter that will end on Mar 2024. Company posted $1.92 million and $2.01 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -44.10% while estimating it to be -65.70% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.87% during past 5 years.

LCTX Dividends

Lineage Cell Therapeutics Inc is more likely to be releasing its next quarterly report on November 09 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders

Insiders are in possession of 4.42% of company’s total shares while institution are holding 41.06 percent of that, with stock having share float percentage of 42.96%. Investors also watch the number of corporate investors in a company very closely, which is 41.06% institutions for Lineage Cell Therapeutics Inc that are currently holding shares of the company. Broadwood Capital, Inc. is the top institutional holder at LCTX for having 34.94 million shares of worth $49.26 million. And as of Jun 29, 2023, it was holding 19.96% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 9.01 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 5.15% of outstanding shares, having a total worth of $12.71 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 4.52 million shares of worth $6.38 million or 2.59% of the total outstanding shares. The later fund manager was in possession of 2.54 million shares on Aug 30, 2023, making its stake of worth around $3.35 million in the company or a holder of 1.45% of company’s stock.

On Key

Related Posts